Ayvakit

Blueprint Medicines Announces Publication in The Lancet Oncology
Blueprint Medicines Announces Publication in The Lancet Oncology

Ayvakit, Clinical Trials, News

Blueprint Medicines Announces Publication in The Lancet Oncology

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

By LRG Staff|2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

Ayvakit, Clinical Trials, News

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

By LRG Staff|2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|